Hansa Biopharma AB (OSTO:HNSA)
kr 40.5 3 (8%) Market Cap: 2.66 Bil Enterprise Value: 3.06 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 77/100

Hansa Biopharma AB Corporate Analyst Meeting Transcript

Oct 29, 2020 / 11:30AM GMT
Release Date Price: kr240.4 (+5.07%)
Klaus Sindahl;publ;Head of IR
Hansa Biopharma AB

()-

Good afternoon, and welcome to the Hansa Biopharma Capital Markets Day. My name is Klaus Sindahl, and I'm Head of Investor Relations at Hansa Biopharma. I'm very pleased that Hansa Biopharma is hosting its third Capital Markets Day here in Copenhagen on the back of an eventful summer with many milestones achieved, milestones which essentially are transforming the company into a commercial stage biopharmaceutical company.

I'm also really excited about the program and the lineup of speakers we have this afternoon. The presentations will take us through very interesting aspects of Hansa Biopharma, both in terms of our recent progress, but also highlight opportunities outside of kidney transplantation in new areas such as gene therapy and autoimmunity. This also underpins that we have a very unique technology asset with very broad commercial opportunities also outside kidney transplantation.

I also wanted to introduce today's moderator, Rachel Curtis Gravesen. Many of you would know Rachel from a long

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot